HomeMYGN • NASDAQ
Myriad Genetics Inc
$12.67
After Hours:
$12.70
(0.24%)+0.030
Closed: Jan 31, 5:44:37 PM GMT-5 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$12.91
Day range
$12.51 - $13.09
Year range
$12.04 - $29.30
Market cap
1.15B USD
Avg Volume
1.07M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD)Sep 2024Y/Y change
Revenue
213.30M11.15%
Operating expense
167.60M4.68%
Net income
-22.10M63.95%
Net profit margin
-10.3667.56%
Earnings per share
0.06300.00%
EBITDA
-2.20M87.36%
Effective tax rate
-4.25%—
Total assets
Total liabilities
(USD)Sep 2024Y/Y change
Cash and short-term investments
99.90M15.76%
Total assets
1.08B-5.90%
Total liabilities
349.60M-24.93%
Total equity
731.70M—
Shares outstanding
91.04M—
Price to book
1.61—
Return on assets
-4.11%—
Return on capital
-5.06%—
Net change in cash
(USD)Sep 2024Y/Y change
Net income
-22.10M63.95%
Cash from operations
700.00K103.17%
Cash from investing
7.50M400.00%
Cash from financing
-3.10M-24.00%
Net change in cash
8.60M131.05%
Free cash flow
16.28M148.95%
About
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity. Wikipedia
Founded
1991
Website
Employees
2,700
Search
Clear search
Close search
Google apps
Main menu